Literature DB >> 11039452

FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features.

K Higashi1, Y Ueda, K Ayabe, A Sakurai, H Seki, Y Nambu, M Oguchi, H Shikata, S Taki, H Tonami, S Katsuda, I Yamamoto.   

Abstract

2-[Fluorine-18]fluoro-2-deoxy-d-glucose (FDG) uptake within the primary lesion correlates with survival on positron emission tomography (PET) studies of patients with non-small cell lung cancer. The more metabolically active the tumour, the worse the outcome. The aim of this study was to determine whether a correlation exists between aggressiveness as determined by pathology and the findings of FDG PET in pulmonary adenocarcinoma. Thirty-five patients with 38 adenocarcinomas of the lung were studied. All patients underwent thoracotomy within 4 weeks of the FDG PET study. For semiquantitative analysis, standardized uptake values (SUVs) were calculated. Patients were classified into high SUV (> or = 4.0) and low SUV (<4.0) groups. The degree of FDG uptake (SUVs) in primary lung lesions was correlated with the histopathological features of aggressiveness (pleural involvement, vascular invasion or lymphatic permeation). The mean SUV of aggressive adenocarcinomas (4.36+/-1.94, n = 22) was higher than that of non-aggressive ones (1.53+/-0.88, n = 16) (P < 0.0001). Tumours with a high FDG uptake have a significantly higher likelihood of aggressiveness than those with a low FDG uptake (P = 0.0004). Analysis by the Kaplan-Meier methods revealed that the groups had different prognoses (log-rank test, P = 0.0099). The high SUV group had a significantly worse prognosis. In conclusion, a correlation was seen between aggressiveness as determined by pathology and glucose metabolism as measured by FDG PET in adenocarcinoma of the lung. FDG PET may be used as a non-invasive diagnostic technique in measuring aggressiveness and prognosis in patients with pulmonary adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11039452     DOI: 10.1097/00006231-200008000-00002

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  31 in total

1.  The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours.

Authors:  Bernadette G Dijkman; Olga C J Schuurbiers; Dennis Vriens; Monika Looijen-Salamon; Johan Bussink; Johanna N H Timmer-Bonte; Miranda M Snoeren; Wim J G Oyen; Henricus F M van der Heijden; Lioe-Fee de Geus-Oei
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-10       Impact factor: 9.236

2.  Diagnostic performance and prognostic impact of FDG-PET in suspected recurrence of surgically treated non-small cell lung cancer.

Authors:  Dirk Hellwig; Andreas Gröschel; Thomas P Graeter; Anne P Hellwig; Ursula Nestle; Hans-Joachim Schäfers; Gerhard W Sybrecht; Carl-Martin Kirsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-09-09       Impact factor: 9.236

3.  Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Authors:  Sophia Koukouraki; Ludwig G Strauss; Vassilios Georgoulias; Michael Eisenhut; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-09       Impact factor: 9.236

Review 4.  PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids.

Authors:  Filippo Lococo; Alfredo Cesario; Massimiliano Paci; Angelina Filice; Annibale Versari; Cristian Rapicetta; Tommaso Ricchetti; Giorgio Sgarbi; Marco Alifano; Alberto Cavazza; Giorgio Treglia
Journal:  Tumour Biol       Date:  2014-05-22

5.  Comparison of prognostic values of primary tumor and nodal 18F-fluorodeoxyglucose uptake in non-small cell lung cancer with N1 disease.

Authors:  Chae Hong Lim; Seung Hyup Hyun; Seung Hwan Moon; Young Seok Cho; Joon Young Choi; Kyung-Han Lee
Journal:  Eur Radiol       Date:  2019-03-21       Impact factor: 5.315

6.  Risk assessment in liposarcoma patients based on FDG PET imaging.

Authors:  Winfried Brenner; Janet F Eary; Willy Hwang; Cheryl Vernon; Ernest U Conrad
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-07-11       Impact factor: 9.236

7.  Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?

Authors:  S M Eschmann; G Friedel; F Paulsen; M Reimold; T Hehr; W Budach; J Scheiderbauer; H J Machulla; H Dittmann; R Vonthein; R Bares
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-11-04       Impact factor: 9.236

8.  Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer.

Authors:  Seung Hwan Moon; Jinho Kim; Je-Gun Joung; Hongui Cha; Woong-Yang Park; Jin Seok Ahn; Myung-Ju Ahn; Keunchil Park; Joon Young Choi; Kyung-Han Lee; Byung-Tae Kim; Se-Hoon Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-25       Impact factor: 9.236

9.  Invasive size is an independent predictor of survival in pulmonary adenocarcinoma.

Authors:  Alain C Borczuk; Fang Qian; Angeliki Kazeros; Jennifer Eleazar; Adel Assaad; Joshua R Sonett; Mark Ginsburg; Lyall Gorenstein; Charles A Powell
Journal:  Am J Surg Pathol       Date:  2009-03       Impact factor: 6.394

10.  18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential.

Authors:  Yuko Watanabe; Hiroaki Suefuji; Yasumitsu Hirose; Hayato Kaida; Gen Suzuki; Jun Uozumi; Etsuyo Ogo; Mayumi Miura; Konomi Takasu; Kanoko Miyazaki; Keita Nakahara; Masatoshi Ishibashi; Takashi Okamura; Koichi Ohshima; Naofumi Hayabuchi
Journal:  Int J Hematol       Date:  2012-12-02       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.